-
Je něco špatně v tomto záznamu ?
Design, synthesis, and biological evaluation of novel 1,2-diaryl-4-substituted-benzylidene-5(4H)-imidazolone derivatives as cytotoxic agents and COX-2/LOX inhibitors
PF. Lamie, JN. Philoppes, L. Rárová,
Jazyk angličtina Země Německo
Typ dokumentu časopisecké články
PubMed
29400411
DOI
10.1002/ardp.201700311
Knihovny.cz E-zdroje
- MeSH
- antiflogistika nesteroidní chemická syntéza chemie farmakologie MeSH
- arachidonát-5-lipoxygenasa metabolismus MeSH
- cyklooxygenasa 2 metabolismus MeSH
- imidazoly chemická syntéza chemie farmakologie MeSH
- inhibitory cyklooxygenasy 2 chemická syntéza chemie farmakologie MeSH
- inhibitory lipoxygenas chemická syntéza chemie farmakologie MeSH
- kultivované buňky MeSH
- lidé MeSH
- molekulární struktura MeSH
- racionální návrh léčiv * MeSH
- simulace molekulového dockingu MeSH
- viabilita buněk účinky léků MeSH
- vztah mezi dávkou a účinkem léčiva MeSH
- vztahy mezi strukturou a aktivitou MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
A new series of 1,2-diaryl-4-substituted-benzylidene-5(4H)-imidazolone derivatives 4a-l was synthesized. Their structures were confirmed by different spectroscopic techniques (IR, 1 H NMR, DEPT-Q NMR, and mass spectroscopy) and elemental analyses. Their cytotoxic activities in vitro were evaluated against breast, ovarian, and liver cancer cell lines and also normal human skin fibroblasts. Cyclooxygenase (COX)-1, COX-2 and lipoxygenase (LOX) inhibitory activities were measured. The synthesized compounds showed selectivity toward COX-2 rather than COX-1, and the IC50 values (0.25-1.7 µM) were lower than that of indomethacin (IC50 = 9.47 µM) and somewhat higher than that of celecoxib (IC50 = 0.071 µM). The selectivity index for COX-2 of the oxazole derivative 4e (SI = 3.67) was nearly equal to that of celecoxib (SI = 3.66). For the LOX inhibitory activity, the new compounds showed IC50 values of 0.02-74.03 µM, while the IC50 of the reference zileuton was 0.83 µM. The most active compound 4c (4-chlorobenzoxazole derivative) was found to have dual COX-2/LOX activity. All the synthesized compounds were docked inside the active site of the COX-2 and LOX enzymes. They linked to COX-2 through the N atom of the azole scaffold, while CO of the oxazolone moiety was responsible for the binding to amino acids inside the LOX active site.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19000940
- 003
- CZ-PrNML
- 005
- 20190114092958.0
- 007
- ta
- 008
- 190107s2018 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1002/ardp.201700311 $2 doi
- 035 __
- $a (PubMed)29400411
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Lamie, Phoebe F $u Faculty of Pharmacy, Department of Pharmaceutical Organic Chemistry, Beni-Suef University, Beni-Suef, Egypt.
- 245 10
- $a Design, synthesis, and biological evaluation of novel 1,2-diaryl-4-substituted-benzylidene-5(4H)-imidazolone derivatives as cytotoxic agents and COX-2/LOX inhibitors / $c PF. Lamie, JN. Philoppes, L. Rárová,
- 520 9_
- $a A new series of 1,2-diaryl-4-substituted-benzylidene-5(4H)-imidazolone derivatives 4a-l was synthesized. Their structures were confirmed by different spectroscopic techniques (IR, 1 H NMR, DEPT-Q NMR, and mass spectroscopy) and elemental analyses. Their cytotoxic activities in vitro were evaluated against breast, ovarian, and liver cancer cell lines and also normal human skin fibroblasts. Cyclooxygenase (COX)-1, COX-2 and lipoxygenase (LOX) inhibitory activities were measured. The synthesized compounds showed selectivity toward COX-2 rather than COX-1, and the IC50 values (0.25-1.7 µM) were lower than that of indomethacin (IC50 = 9.47 µM) and somewhat higher than that of celecoxib (IC50 = 0.071 µM). The selectivity index for COX-2 of the oxazole derivative 4e (SI = 3.67) was nearly equal to that of celecoxib (SI = 3.66). For the LOX inhibitory activity, the new compounds showed IC50 values of 0.02-74.03 µM, while the IC50 of the reference zileuton was 0.83 µM. The most active compound 4c (4-chlorobenzoxazole derivative) was found to have dual COX-2/LOX activity. All the synthesized compounds were docked inside the active site of the COX-2 and LOX enzymes. They linked to COX-2 through the N atom of the azole scaffold, while CO of the oxazolone moiety was responsible for the binding to amino acids inside the LOX active site.
- 650 _2
- $a antiflogistika nesteroidní $x chemická syntéza $x chemie $x farmakologie $7 D000894
- 650 _2
- $a arachidonát-5-lipoxygenasa $x metabolismus $7 D001094
- 650 _2
- $a viabilita buněk $x účinky léků $7 D002470
- 650 _2
- $a kultivované buňky $7 D002478
- 650 _2
- $a cyklooxygenasa 2 $x metabolismus $7 D051546
- 650 _2
- $a inhibitory cyklooxygenasy 2 $x chemická syntéza $x chemie $x farmakologie $7 D052246
- 650 _2
- $a vztah mezi dávkou a účinkem léčiva $7 D004305
- 650 12
- $a racionální návrh léčiv $7 D015195
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imidazoly $x chemická syntéza $x chemie $x farmakologie $7 D007093
- 650 _2
- $a inhibitory lipoxygenas $x chemická syntéza $x chemie $x farmakologie $7 D016859
- 650 _2
- $a simulace molekulového dockingu $7 D062105
- 650 _2
- $a molekulární struktura $7 D015394
- 650 _2
- $a vztahy mezi strukturou a aktivitou $7 D013329
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Philoppes, John N $u Faculty of Pharmacy, Department of Pharmaceutical Organic Chemistry, Beni-Suef University, Beni-Suef, Egypt.
- 700 1_
- $a Rárová, Lucie $u Department of Chemical Biology and Genetics, Centre of the Region Haná for Biotechnological and Agricultural Research, Institute of Experimental Botany ASCR and Palacký University, Olomouc, Czech Republic.
- 773 0_
- $w MED00000507 $t Archiv der Pharmazie $x 1521-4184 $g Roč. 351, č. 3-4 (2018), s. e1700311
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29400411 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190107 $b ABA008
- 991 __
- $a 20190114093207 $b ABA008
- 999 __
- $a ok $b bmc $g 1364909 $s 1039063
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 351 $c 3-4 $d e1700311 $e 20180205 $i 1521-4184 $m Archiv der Pharmazie $n Arch Pharm $x MED00000507
- LZP __
- $a Pubmed-20190107